Mycobacterium tuberculosis in solid organ transplant recipients

American Journal of Transplantation

Volumn 9, Issue SUPPL. 4, 2009, Pages

  Subramanian, A ^a   Dorman, S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infection; Latent tuberculosis; Transplant; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OKT 3; PYRAZINAMIDE; PYRIDOXINE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; T LYMPHOCYTE ANTIBODY;

GRAFT RECIPIENT; HUMAN; LIVER FUNCTION TEST; LIVER TOXICITY; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; ORGAN TRANSPLANTATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 72949116194     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02894.x     Document Type: Review

References (41)

1. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005 40 : 581 587. (Pubitemid 40270229)
2. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998 27 : 1266 1277.
3. Ginsburg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nature Med 2007 13 : 290 294.
4. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis. Nature Med 2007 13 : 295 298.
5. Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003 167 : 603 662.
6. Controlling Tuberculosis in the United States. This Official Joint Statement of the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America was approved by the ATS Board of Directors, June 2004, the Centers for Disease Control and Prevention, November 2004, and the IDSA Board of Directors, March 2005. Am J Respir Crit Care Med 2005 172 : 1169 1227.
7. Mycobacterium tuberculosis, in Guidelines for the Prevetnion and Management of Infectious Complications of Solid Organ Transplantation. Am J Transplant 2004 4 (Suppl 10 37 41.
8. Weisdorf D. Typical and atypical Mycobacterium infections after hemopoietic stem cell or solid organ transplantation. In : Bowden RA, Ljungman P, Paya CV, eds. Transplant Infections. 2nd Ed. Philadelphia, PA : Lippincott Williams & Wilkins 2003 : 250 258.
9. Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P. Tuberculosis in solid-organ transplant recipients: Consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009 49 : 1276 1284.
10. Torre-Cisneros J, Doblas A, Aguado JM et al. Tuberculosis after solid-organ transplant:incidence, risk factors, and clinical characteristics in the RESITRA (Spanish network of Infection in Transplantation) cohort. Clin Infect Dis 2009 48 : 1657 1665.
11. Vikrant S, Agarwal SK, Gupta S et al. Prospective randomized controlled trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005 7 : 99 108.
12. Agarwal SK, Gupta S, Dash SC et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipients. Int Urol Nephrol 2004 36 : 425 431.
13. John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994 57 : 1683 1684.
14. Aguado JM, Herrero JA, Gavalda J et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997 63 : 1278 1286.
15. Benito N, Sued O, Moreno A et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002 74 : 1381 1386.
16. EPBG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections: Tuberculosis. Nephrol Dial Transplant 2002 17 (Suppl 39 43.
17. Delaney V, Sumrani N, Hong JH, Sommer B. Mycobacterial infections in renal allograft recipients. Transplant Proc 1993 25 : 2288 2289.
18. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994 58 : 301 306.
19. Higgins RSD, Kusne S, Reyes J et al. Mycobacterium tuberculosis after liver transplantation: Management and guidelines for prevention. Clin Transplant 1992 6 : 81 90.
20. Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995 21 : 398 402.
21. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995 152 : 374 376.
22. Korner MM, Hirata N, Tenderich G et al. Tuberculosis in heart transplant recipients. Chest 1997 111 : 365 369.
23. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996 61 : 211 215.
24. John GT, Vincent L, Jeyaseelan L, Jacob CK, Shastry JC. Cyclosporine immunosuppression and mycobacterial infections. Transplantation 1994 58 : 247 249.
25. Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation 1984 38 : 514 516.
26. Sundberg R, Shapiro R, Darras F et al. A tuberculosis outbreak in a renal transplant program. Transplant Proc 1991 23 : 3091 3092.
27. Basiri A, Hosseini-Moghaddam, Simforoosh N et al. The risk factors and laboratory diagnostics for postrenal transplant tuberculosis: A case-control, country-wide study on definitive cases. Transplant Infect Dis 2008 10 : 231 235.
28. Lattes R, Radisic M, Rial M et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999 1 : 98 104.
29. Mazurek GH, Jereb J, Lobue P et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005 54 : 49 55.
30. Pai M, Zwerling A, Menzies D. Systematic review: T cell based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008 149 : 177 184.
31. Manuel O, Humar A, Preiksaitis J et al. Comparison of quantifereon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007 7 : 2797 2801.
32. Rubin RH. Infection in the organ transplant patient. In : Rubin RH and Young LS, eds. Clinical approach to infection in the compromised host. 4th Ed. New York and London : Plenum Press, 2002.
33. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000 161 (4 Pt 2 S221 247.
34. Thomas PA, Jr., Mozes MF, Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979 114 : 597 599.
35. Schluger LK, Sheiner PA, Jonas M et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996 63 : 364 369.
36. Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis 1973 107 : 523 529.
37. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997 11 : 34 37.
38. Singh N, Wagener MM, Gayowski T. Safety and efficiacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002 74 : 892 895.
39. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007 83 : 1557 1562.
40. Chang KC, Leung CC, Yew WW et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006 174 : 1153 1158.
41. McGregor MM, Olliaro P, Wolmarans L et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996 154 : 1462 1467.